Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis.

MLA

Stillger, Maren Nicole, et al. “Changes in Calpain-2 Expression during Glioblastoma Progression Predisposes Tumor Cells to Temozolomide Resistance by Minimizing DNA Damage and P53-Dependent Apoptosis.” Cancer Cell International, vol. 23, no. 1, Mar. 2023, pp. 1–23. EBSCOhost, https://doi.org/10.1186/s12935-023-02889-8.

APA

Stillger, M. N., Chen, C.-Y., Lai, Z. W., Li, M., Schäfer, A., Pagenstecher, A., Nimsky, C., Bartsch, J. W., & Schilling, O. (2023). Changes in calpain-2 expression during glioblastoma progression predisposes tumor cells to temozolomide resistance by minimizing DNA damage and p53-dependent apoptosis. Cancer Cell International, 23(1), 1–23. https://doi.org/10.1186/s12935-023-02889-8

Chicago

Stillger, Maren Nicole, Chia-Yi Chen, Zon Weng Lai, Mujia Li, Agnes Schäfer, Axel Pagenstecher, Christopher Nimsky, Jörg Walter Bartsch, and Oliver Schilling. 2023. “Changes in Calpain-2 Expression during Glioblastoma Progression Predisposes Tumor Cells to Temozolomide Resistance by Minimizing DNA Damage and P53-Dependent Apoptosis.” Cancer Cell International 23 (1): 1–23. doi:10.1186/s12935-023-02889-8.